| Name | Title | Contact Details |
|---|
NuVasive® is an innovative medical device company focused on developing minimally disruptive surgical products and procedures for the spine. Our mission is to improve the lives of patients who suffer from debilitating back, neck, or leg pain by creating cutting-edge products and procedures that revolutionize spine surgery through focusing on Speed of Innovation®, Absolute Responsiveness®, and Superior Clinical Results. Through innovative technological advancements, NuVasive has successfully progressed major spine surgery to where many patients have experienced extraordinary results—they are often walking the same day of surgery, experiencing less blood loss, spending less time in the hospital, and going back to work within four to six weeks (versus six months). NuVasive is the third largest medical device company in the global spine industry. We feature more than 90 products spanning lumbar, thoracic, and cervical applications, neuromonitoring services, and a biologics portfolio. Our products have been used in hundreds of thousands of spine surgeries. NuVasive had revenues of $811 million in 2015, including sales in over 30 countries, and employs more than 1,600 people globally. Corporate headquarters are in San Diego, California and Amsterdam, the Netherlands serves as international headquarters. The company has additional offices in the U.S. located in the states of Tennessee, Ohio, Maryland, and California. Internationally, NuVasive has additional offices located Puerto Rico, the United Kingdom, Germany, Italy, Australia, Spain, Singapore, and Japan.
Sinclair Pharmaceuticals, Ltd. is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EndoChoice Based in Atlanta GA, EndoChoice® is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy® System (Fuse®). 2014 marked the fifth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine.
Our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. The pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. The team is complemented by world-class medical advisors. Our products have been organically conceived, researched and developed by the Company and all manufacturing activities are conducted to ensure compliance with the U.S. Food and Drug Administration (FDA) per the requirements of 21 CFR 820, as well as ISO 13485. Femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the U.S. Food and Drug Administration (FDA), European Union, Canada, and Japan with other select countries in process. Making a difference in the lives of women one product at a time is a great privilege and serves to drive the Company`s mission.
Lemonaid Health is leading a second wave of telehealth where technology algorithms power quality care. Lemonaid leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumer for less than typical co-pays.